Literature DB >> 16517702

Attenuation of IL-7 receptor signaling is not required for allelic exclusion.

Wynette M Will1, Joshua D Aaker, Matthew A Burchill, Ian R Harmon, Jennifer J O'Neil, Christine A Goetz, Keli L Hippen, Michael A Farrar.   

Abstract

Allelic exclusion prevents pre-B cells from generating more than one functional H chain, thereby ensuring the formation of a unique pre-BCR. The signaling processes underlying allelic exclusion are not clearly understood. IL-7R-dependent signals have been clearly shown to regulate the accessibility of the Ig H chain locus. More recent work has suggested that pre-BCR-dependent attenuation of IL-7R signaling returns the H chain loci to an inaccessible state; this process has been proposed to underlie allelic exclusion. Importantly, this model predicts that preventing pre-BCR-dependent down-regulation of IL-7R signaling should interfere with allelic exclusion. To test this hypothesis, we made use of transgenic mice that express a constitutively active form of STAT5b (STAT5b-CA). STAT5b-CA expression restores V(D)J recombination in IL-7R(-/-) B cells, demonstrating that IL-7 regulates H chain locus accessibility and V(D)J recombination via STAT5 activation. To examine the effects of constitutively active STAT5b on allelic exclusion, we crossed STAT5b-CA mice (which express the IgM(b) allotype) to IgM(a) allotype congenic mice. We found no difference in the percentage of IgM(a)/IgM(b)-coexpressing B cells in STAT5b-CA vs littermate control mice; identical results were observed when crossing STAT5b-CA mice with hen egg lysozyme (HEL) H chain transgenic mice. The HEL transgene enforces allelic exclusion, preventing rearrangement of endogenous H chain genes; importantly, rearrangement of endogenous H chain genes was suppressed to a similar degree in STAT5b-CA vs HEL mice. Thus, attenuation of IL-7R/STAT5 signaling is not required for allelic exclusion.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16517702     DOI: 10.4049/jimmunol.176.6.3350

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  6 in total

1.  A developmentally controlled competitive STAT5-PU.1 DNA binding mechanism regulates activity of the Ig κ E3' enhancer.

Authors:  Suchita Hodawadekar; Kyoungsook Park; Michael A Farrar; Michael L Atchison
Journal:  J Immunol       Date:  2012-01-25       Impact factor: 5.422

2.  A Flt3- and Ras-dependent pathway primes B cell development by inducing a state of IL-7 responsiveness.

Authors:  Lin-Xi Li; Christine A Goetz; Casey D S Katerndahl; Nobuo Sakaguchi; Michael A Farrar
Journal:  J Immunol       Date:  2010-01-11       Impact factor: 5.422

3.  Linked T cell receptor and cytokine signaling govern the development of the regulatory T cell repertoire.

Authors:  Matthew A Burchill; Jianying Yang; Kieng B Vang; James J Moon; H Hamlet Chu; Chan-Wang J Lio; Amanda L Vegoe; Chyi-Song Hsieh; Marc K Jenkins; Michael A Farrar
Journal:  Immunity       Date:  2008-01       Impact factor: 31.745

4.  IL-7 functionally segregates the pro-B cell stage by regulating transcription of recombination mediators across cell cycle.

Authors:  Kristen Johnson; Julie Chaumeil; Mariann Micsinai; Joy M H Wang; Laura B Ramsey; Gisele V Baracho; Robert C Rickert; Francesco Strino; Yuval Kluger; Michael A Farrar; Jane A Skok
Journal:  J Immunol       Date:  2012-05-11       Impact factor: 5.422

5.  RAG-1 and ATM coordinate monoallelic recombination and nuclear positioning of immunoglobulin loci.

Authors:  Susannah L Hewitt; Bu Yin; Yanhong Ji; Julie Chaumeil; Katarzyna Marszalek; Jeannette Tenthorey; Giorgia Salvagiotto; Natalie Steinel; Laura B Ramsey; Jacques Ghysdael; Michael A Farrar; Barry P Sleckman; David G Schatz; Meinrad Busslinger; Craig H Bassing; Jane A Skok
Journal:  Nat Immunol       Date:  2009-06       Impact factor: 25.606

6.  Chromosomal position of a VH gene segment determines its activation and inactivation as a substrate for V(D)J recombination.

Authors:  Jamie Geier Bates; Dragana Cado; Hector Nolla; Mark S Schlissel
Journal:  J Exp Med       Date:  2007-12-03       Impact factor: 14.307

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.